Playback speed
10 seconds
CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC
By
Lilly Medical Affairs
FEATURING
Joyce O’Shaughnessy
By
Lilly Medical Affairs
FEATURING
Joyce O’Shaughnessy
1,331 views
July 24, 2024
In this video, Dr. Joyce O’Shaughnessy shares her expertise on the standard of care first-line treatment for patients with HR+, HER2- MBC and the efficacy and safety data for CDK4/6 inhibitors in this setting.
To access additional videos and download free resources, click here.
VV-OTHR-US-DEL-3129 © 2024 Lilly USA, LLC. All Rights Reserved.
Comments are disabled for this content.